Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

This study is looking for adults aged 18 and over who have been diagnosed with certain types of blood cancer. This includes specific lymphomas such as extranodal, splenic, or nodal Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, or Mantle Cell Lymphoma. We are also looking for people with Chronic Lymphocytic Leukaemia (CLL) or Waldenström's Macroglobulinemia.

Crucially, your cancer must either have come back after previous treatment, or not responded well to earlier treatments. For some types of lymphoma, it must also be a form that has become more aggressive or for which an autologous stem cell transplant isn't suitable. You must also have active disease that your doctor believes needs treating and for which there is enough disease size that can be measured.

Your medical team will carefully check your specific diagnosis and medical history against a full list of criteria to see if this study could be a suitable option for you. Not everyone with these conditions will be able to join, as there are often detailed reasons why a particular study might not be the best fit for an individual patient.

If you join this study, you will be given the study medicine, sonrotoclax, which could be on its own or with zanubrutinib and obinutuzumab. You will have regular visits to the clinic for check-ups, where doctors and nurses will monitor your health, check for any side effects, and see how the treatment is affecting your cancer. These visits will involve physical exams, blood tests, and scans (like CT scans) to measure your disease. The total duration of your participation will depend on how you respond to the treatment, but these types of studies typically involve an initial period of treatment, followed by regular follow-up for a longer time.